Detecting BRAF (V600E) Mutation in FFPE or Blood Samples
When mutated, oncogenes can convert normal cells to cancer cells. BRAF is one of the oncogenes that controls transduction of chemical signal from outside the cells to nucleus. As a member of the RAS/MAPK pathway, the BRAF gene product, the B-Raf protein, regulates cell growth and division.
BRAF (V600E) mutation, the most common BRAF mutation, has been found in different types of cancer including melanoma, colon cancer, and hairy cell leukemia. BRAF mutations occur between 40 and 60% of melanoma and 90% of these mutations are V600E. It has been shown BRAF (V600E) is more sensitive to BRAF inhibitors and some of these inhibitors have demonstrated clinical efficacy for malignant melanoma metastasis and increase patient overall survival. Identification of the BRAF (V600E) mutation may provide benefits to the patients who are selected for BRAF inhibitor therapy.
Using the XNA technology, we have developed gene mutation detection kits to identify BRAF (V600E) and other important cancer driver genes using a simple and fast qPCR assay that regular qPCR can’t do. We recently have also celebrated our 7th anniversary and reward our researchers with these mutation kits.
Dealing with the Respiratory Viruses that Cause Covid-19 or Flu
Influenza and COVID-19: what are they in common? Currently, the two most important respiratory viruses the healthcare authority is paying attention to are SARS-COV-2 (causing COVID-19) and influenza A and B viruses (Flu A and B). The Flu A and B viruses (named by the...
Early Cancer Detection Will Save More Lives
Cancer deaths due to failure of early detection According to the American Cancer Society researchers, it is estimated that there will be more than 600,000 people die of cancer, and 1.9 million new cancer cases in the US in 2021 alone. Seventy-one percent of the...
Assay Detects Precancerous Colorectal Cancer Lesions & Mutations
Written by Chris Wolskiat Clinical Lab Products Read the article on Clinical Lab Products
DiaCarta Positioning Liquid Biopsy Assay to Gauge Chemotherapy Response in Multiple Cancers
Written by John Gilmore at genomeweb Read the article on genomeweb Download the article NEW YORK – On the heels of newly published data, Diacarta plans to invest further in blood-based testing to determine the utility of its assays to predict drug response in patients...
KRAS Codon 12 Mutations and Detection
Next-generation sequencing (NGS) is a powerful tool that has seen a fast increase in clinical labs although only a few NGS tests have been approved by the FDA. However, there have been a lot of debate on if variants from NGS sequencing should be confirmed either by Sanger sequencing, the gold standard, or other techniques such as quantitative PCR, or the combination, or other methods.
HPV-driven Cancers and Somatic Mutations in These Cancers
Next-generation sequencing (NGS) is a powerful tool that has seen a fast increase in clinical labs although only a few NGS tests have been approved by the FDA. However, there have been a lot of debate on if variants from NGS sequencing should be confirmed either by Sanger sequencing, the gold standard, or other techniques such as quantitative PCR, or the combination, or other methods.